Replies to post #116777 on Biotech Values

[jq1234]

it may be a stretch but the BMY data is another notch validating immunotherapy (specifically t-cell mediated) for cancer - something that imo bolster's MITI's overall approach (although the ALL data stands on its own)

It's not a stretch at all. MITI has been choosing right indication for BiTE cooperation with big pharma: Bayer Prostate, BI on MM, and SA I suspend Melanoma.

[tony111]

Something is seriously wrong with micromet ..... They might be seeing redflags in their open label pivotal trial.